169 related articles for article (PubMed ID: 33419372)
1. NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Audrito V; Messana VG; Moiso E; Vitale N; Arruga F; Brandimarte L; Gaudino F; Pellegrino E; Vaisitti T; Riganti C; Piva R; Deaglio S
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419372
[TBL] [Abstract][Full Text] [Related]
2. Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.
Audrito V; Moiso E; Ugolini F; Messana VG; Brandimarte L; Manfredonia I; Bianchi S; De Logu F; Nassini R; Szumera-Ciećkiewicz A; Taverna D; Massi D; Deaglio S
J Transl Med; 2022 Mar; 20(1):118. PubMed ID: 35272691
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S
J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612
[TBL] [Abstract][Full Text] [Related]
4. Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT).
Audrito V; Managò A; Gaudino F; Deaglio S
Semin Cell Dev Biol; 2020 Feb; 98():192-201. PubMed ID: 31059816
[TBL] [Abstract][Full Text] [Related]
5. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Ohanna M; Cerezo M; Nottet N; Bille K; Didier R; Beranger G; Mograbi B; Rocchi S; Yvan-Charvet L; Ballotti R; Bertolotto C
Genes Dev; 2018 Mar; 32(5-6):448-461. PubMed ID: 29567766
[TBL] [Abstract][Full Text] [Related]
6. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
7. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
8. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
9. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
10. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
11. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
12. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
13. NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets.
Indini A; Fiorilla I; Ponzone L; Calautti E; Audrito V
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077374
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
15. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
Audrito V; Managò A; Zamporlini F; Rulli E; Gaudino F; Madonna G; D'Atri S; Antonini Cappellini GC; Ascierto PA; Massi D; Raffaelli N; Mandalà M; Deaglio S
Oncotarget; 2018 Apr; 9(27):18997-19005. PubMed ID: 29721178
[TBL] [Abstract][Full Text] [Related]
16.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
17. PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.
Audrito V; Serra S; Stingi A; Orso F; Gaudino F; Bologna C; Neri F; Garaffo G; Nassini R; Baroni G; Rulli E; Massi D; Oliviero S; Piva R; Taverna D; Mandalà M; Deaglio S
Oncotarget; 2017 Feb; 8(9):15894-15911. PubMed ID: 28199980
[TBL] [Abstract][Full Text] [Related]
18. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
[TBL] [Abstract][Full Text] [Related]
19. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI
Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391
[TBL] [Abstract][Full Text] [Related]
20. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
